Drug intelligence / Profile preview

Enli

Development stage: Unknown
Lead developer: Amgen
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

Enli is a brand name for etanercept, a recombinant human type II tumor necrosis factor receptor-antibody fusion protein. It functions as a tumor necrosis factor (TNF) inhibitor, blocking the activity of TNF to reduce inflammation and immune responses. It is used in the treatment of autoimmune diseases such as rheumatoid arthritis. Enli is marketed in China and is the reference product (or a licensed version of it) for etanercept in that region.

Brand names: Enli
Other names: 恩利

Targets

LTA (Lymphotoxin-alpha)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on Enli.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enli.

Explore the full profile